CPRX Valuation

Catalyst Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

20.610

+0.38(1.878%)1D

Overview
Forecast
Valuation
Earnings

CPRX Relative Valuation

CPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CPRX is overvalued; if below, it's undervalued.

Historical Valuation

Catalyst Pharmaceuticals Inc (CPRX) is now in the Fair zone, suggesting that its current forward PE ratio of 15.21 is considered Fairly compared with the five-year average of 13.77. The fair price of Catalyst Pharmaceuticals Inc (CPRX) is between 14.59 to 24.06 according to relative valuation methord.

Relative Value

Fair Zone

14.59-24.06

Current Price：20.23

Fair

15.21

Trailing

Forward

8.05

EV/EBITDA

Catalyst Pharmaceuticals Inc. (CPRX) has a current EV/EBITDA of 8.05. The 5-year average EV/EBITDA is 2.95. The thresholds are as follows: Strongly Undervalued below -5.80, Undervalued between -5.80 and -1.43, Fairly Valued between 7.32 and -1.43, Overvalued between 7.32 and 11.70, and Strongly Overvalued above 11.70. The current Forward EV/EBITDA of 8.05 falls within the Overvalued range.

8.98

EV/EBIT

Catalyst Pharmaceuticals Inc. (CPRX) has a current EV/EBIT of 8.98. The 5-year average EV/EBIT is 8.62. The thresholds are as follows: Strongly Undervalued below 1.87, Undervalued between 1.87 and 5.24, Fairly Valued between 11.99 and 5.24, Overvalued between 11.99 and 15.37, and Strongly Overvalued above 15.37. The current Forward EV/EBIT of 8.98 falls within the Historic Trend Line -Fairly Valued range.

4.44

Catalyst Pharmaceuticals Inc. (CPRX) has a current PS of 4.44. The 5-year average PS is 3.98. The thresholds are as follows: Strongly Undervalued below 2.22, Undervalued between 2.22 and 3.10, Fairly Valued between 4.86 and 3.10, Overvalued between 4.86 and 5.74, and Strongly Overvalued above 5.74. The current Forward PS of 4.44 falls within the Historic Trend Line -Fairly Valued range.

10.22

P/OCF

Catalyst Pharmaceuticals Inc. (CPRX) has a current P/OCF of 10.22. The 5-year average P/OCF is 10.25. The thresholds are as follows: Strongly Undervalued below 5.47, Undervalued between 5.47 and 7.86, Fairly Valued between 12.64 and 7.86, Overvalued between 12.64 and 15.03, and Strongly Overvalued above 15.03. The current Forward P/OCF of 10.22 falls within the Historic Trend Line -Fairly Valued range.

10.22

P/FCF

Catalyst Pharmaceuticals Inc. (CPRX) has a current P/FCF of 10.22. The 5-year average P/FCF is 10.62. The thresholds are as follows: Strongly Undervalued below 5.83, Undervalued between 5.83 and 8.22, Fairly Valued between 13.01 and 8.22, Overvalued between 13.01 and 15.41, and Strongly Overvalued above 15.41. The current Forward P/FCF of 10.22 falls within the Historic Trend Line -Fairly Valued range.

Catalyst Pharmaceuticals Inc (CPRX) has a current Price-to-Book (P/B) ratio of 2.89. Compared to its 3-year average P/B ratio of 4.28 , the current P/B ratio is approximately -32.46% higher. Relative to its 5-year average P/B ratio of 3.80, the current P/B ratio is about -23.84% higher. Catalyst Pharmaceuticals Inc (CPRX) has a Forward Free Cash Flow (FCF) yield of approximately 11.10%. Compared to its 3-year average FCF yield of 3.73%, the current FCF yield is approximately 197.09% lower. Relative to its 5-year average FCF yield of 6.02% , the current FCF yield is about 84.21% lower.

2.89

P/B

Median3y

4.28

Median5y

3.80

11.10

FCF Yield

Median3y

3.73

Median5y

6.02

Competitors Valuation Multiple

The average P/S ratio for CPRX's competitors is 5.18, providing a benchmark for relative valuation. Catalyst Pharmaceuticals Inc Corp (CPRX) exhibits a P/S ratio of 4.44, which is -14.28% above the industry average. Given its robust revenue growth of 19.44%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CPRX.O

Catalyst Pharmaceuticals Inc

Kiniksa Pharmaceuticals International PLC

Centessa Pharmaceuticals PLC

Supernus Pharmaceuticals Inc

3.13

-1.71%

2.39B

Performance Decomposition

Market capitalization of CPRX decreased by 0.10% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 122.71M to 146.56M.

The secondary factor is the Margin Expansion, contributed 6.95%to the performance.

Overall, the performance of CPRX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

19.44%

122.71M → 146.56M

Revenue Growth

6.95%

33.24 → 35.55

Margin Expansion

-26.49%

16.69 → 12.27

P/E Change

-0.10%